Page results
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
The Clinical Research Facility at UCLH has been awarded £10 million in funding to deliver cutting edge early phase health research in areas including cancer and dementia.
-
UCLH has recruited the first participant for a new UK based study for Parkinson’s Disease (PD). The ASPro-PD study is testing whether treatment with a drug called ambroxol is associated with an improvement in motor and non-motor function compared with placebo.
-
UCLH will play a vital role in a new respiratory virus study.
-
Read more about the NHS Staff Survey 2024 - we’re the top acute trust to work at for third year running!
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
The Royal National ENT Voice Centre is a national and international multidisciplinary centre for voice disorders. The voice clinic at the RNENT is one of the oldest in the UK.
-
Researchers at UCLH have begun a study which could set the foundations for how booster COVID-19 vaccinations are delivered in the future.
-
CAMLIS is the Royal London Hospital for Integrated Medicine (RLHIM) Complementary and Alternative Medicine Information and Library Service and is situated on the ground floor of the hospital.
-
North Mid, UCLH and Whittington Health are running a fun, uplifting, informative event for people with sickle cell on Saturday 25th June 2022.
File results
-
FOI/2023/0296 - Consultant workforce information
-
FOI/2023/0300 - Post-mortem examinations for 2019, 2020, 2021 and 2022
-
FOI/2023/0301 - Meat served at the Trust that may contain nitrates or nitrites
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases